Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
ICRF-187 (NSC-169780), the (+) enantiomer of the racemic antineoplastic agent ICRF-159 (NSc-129943), was administered intravenously for five days every three weeks to 18 patients in a phase I study. Leukopenia was the dose-limiting toxicity. Mild reversible elevations in SGOT and bilirubin were common. Other toxicities were mild and infrequent. Recommended doses of ICRF-187 for phase II studies are 800 mg/m2 for heavily pretreated patients and 1250 mg/m2 for patients with little or no prior therapy. A daily five day intravenous schedule should be used. Other potential clinical uses of ICRF-187 are discussed.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006098:Granulocytes; D006801:Humans; D007263:Infusions, Parenteral; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D009196:Myeloproliferative Disorders / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D011929:Razoxane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010879:Piperazines; D011929:Razoxane